Literature DB >> 15120612

Expression and secretion of human glucocerebrosidase mediated by recombinant lentivirus vectors in vitro and in vivo: implications for gene therapy of Gaucher disease.

Eun Young Kim1, Young Bin Hong, Zhennan Lai, Hyon J Kim, Youl-Hee Cho, Roscoe O Brady, Sung-Chul Jung.   

Abstract

Gaucher disease is a lysosomal storage disorder resulting from a deficiency of glucocerebrosidase (GC). In this study, we showed that vascular and hepatic delivery of a HIV-1-based lentivirus vector encoding human GC cDNA produced therapeutic levels of GC protein. A high level of expression of GC was produced in cultured fibroblasts derived from patients with Gaucher disease by transducing the cells with recombinant lentivirus vectors. GC secreted by transduced fibroblasts was taken up by adjacent GC-deficient cells by endocytosis. Intraportal administration of lenti-EF-GC viral vector resulted in efficient transduction and expression of the GC. Vascular delivery of vector resulted in high levels of GC expression in mice that persisted in most organs over the four months. No significant abnormalities were found attributable to recombinant lentivirus vectors in any of the tissues examined. This study represents an initial step toward gene transfer using recombinant lentivirus vectors for treatment of Gaucher disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15120612     DOI: 10.1016/j.bbrc.2004.04.040

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  Revised recommendations for the management of Gaucher disease in children.

Authors:  Paige Kaplan; Hagit Baris; Linda De Meirleir; Maja Di Rocco; Amal El-Beshlawy; Martina Huemer; Ana Maria Martins; Ioana Nascu; Marianne Rohrbach; Lynne Steinbach; Ian J Cohen
Journal:  Eur J Pediatr       Date:  2012-07-08       Impact factor: 3.183

2.  VP22 enhances the expression of glucocerebrosidase in human Gaucher II fibroblast cells mediated by lentiviral vectors.

Authors:  Gui-shan Jin; Gui-dong Zhu; Zhi-gang Zhao; Fu-sheng Liu
Journal:  Clin Exp Med       Date:  2011-08-28       Impact factor: 3.984

3.  Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders.

Authors:  E Aguilar Salegio; A P Kells; R M Richardson; P Hadaczek; J Forsayeth; J Bringas; S P Sardi; M A Passini; L S Shihabuddin; S H Cheng; M S Fiandaca; K S Bankiewicz
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

4.  Feasibility of gene therapy in Gaucher disease using an adeno-associated virus vector.

Authors:  Young Bin Hong; Eun Young Kim; Han-Wook Yoo; Sung-Chul Jung
Journal:  J Hum Genet       Date:  2004-09-14       Impact factor: 3.172

Review 5.  Gaucher disease: new developments in treatment and etiology.

Authors:  Ozgur Harmanci; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

6.  Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain.

Authors:  Ernesto A Salegio; Lluis Samaranch; Russell W Jenkins; Christopher J Clarke; Clementine Lamarre; Janine Beyer; Adrian P Kells; John Bringas; Waldy San Sebastian; R Mark Richardson; Kate H Rosenbluth; Yusuf A Hannun; Krystof S Bankiewicz; John Forsayeth
Journal:  Hum Gene Ther       Date:  2012-08       Impact factor: 5.695

7.  Lentivirus vector-mediated mitofusin-2 overexpression in rat ovary changes endocrine function and promotes follicular development in vivo.

Authors:  Xiaojing Hu; Xiubing Lei; Jidong Wang; Hongjuan Pan; Cong Li; Zhenwei Yao
Journal:  Exp Ther Med       Date:  2014-07-09       Impact factor: 2.447

8.  Effects of gene therapy on cardiovascular symptoms of lysosomal storage diseases.

Authors:  Edina Poletto; Gabriela Pasqualim; Roberto Giugliani; Ursula Matte; Guilherme Baldo
Journal:  Genet Mol Biol       Date:  2019-05-23       Impact factor: 1.771

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.